We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Bank of America, UnitedHealth, Intel, UPS and Celgene
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 01, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeBank of America (NYSE:BAC – Free Report), UnitedHealth (NYSE:(UNH - Free Report) – Free Report), Intel (NASDAQ:INTC – Free Report), UPS (NYSE:(UPS - Free Report) – Free Report) and Celgene (NASDAQ: – Free Report).
Top Analyst Reports for B of A, UnitedHealth, Intel & More
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Bank of America (NYSE:(BAC - Free Report) – Free Report), UnitedHealth (NYSE:(UNH - Free Report) – Free Report), Intel (NASDAQ:(INTC - Free Report) – Free Report) and Celgene (NASDAQ: – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Bank of America shares have outperformed the Zacks Major Regional Banks industry over the last six months, gaining +5.9% vs. +5.3%. The company’s second quarter 2017 earnings outpaced expectations. Improvement in net interest income, higher investment banking fees and lower provisions supported the results.
Rising interest rates, increase in loan and deposit balances, efforts to streamline and simplify operations, and potentially fewer regulations are expected to continue supporting the company's profitability going forward. However, fee income growth remains a key concern. Specifically, a fall in mortgage banking income owing to lower volumes and decline in refinancing along with uncertainty related to performance of capital markets are major concerns for the Zacks analyst.
Shares ofCelgene have gained +17.5% year to date, outperforming the Zacks Biomedical and Genetics sector which has gained +10.5% over the same period. The company’s second-quarter results were strong with the company beating on both earnings and sales estimates. Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration.
The Zacks analyst likes the consecutive increase in annual earnings guidance. Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue.
UnitedHealth’s robust Government business and continued strong growth at Optum are driving long-term growth. Its international business, growing membership and strong capital position are the other positives. In the most recently reported quarter, the company reported better-than-expected earnings, driven by an increase in revenues and membership.
Encouraged by its impressive first-half earnings, the company raised 2017 guidance. Meanwhile, the company has reduced its exposure to the troubled public exchange business. Though this move will shield it from losses in this business, premium revenues are likely to be affected. UnitedHealth shares have underperformed the Zacks Medical Insurance industry in the year-to-date period (up +19.7% vs. +22.2%).
Shares of Intel have gained only +2.5% since election results were announced on Nov 8, in contrast to the broader Technology sector (up +18.6%) as well as the red-hot semiconductors space (up +28.3%). Intel’s second-quarter 2017 results demonstrated the company’s growing focus on the data-centric part of its business.
The recent launch of Xeon Scalable is anticipated to benefit its footprint in the data center as well as AI and IoT space, going forward. Further, anticipated improvement in cost structure and lower spending, primarily due to improving operational efficiency will aid in expansion of margins over time. Additionally, aggressive share buybacks will boost the bottom line in 2017.
Intel’s weak price performance can be attributed to growing competition from AMD in the data center space. Meanwhile, top-PC makers like HP, Lenovo, and Asus are set to launch PCs based on Qualcomm’s ARM-based Snapdragon processor, which intensifies competition for Intel. This is a significant headwind amid declining PC shipments.
Other noteworthy reports we are featuring today include UPS (NYSE:(UPS - Free Report) – Free Report).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 to Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and 90.2% respectively.
This outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11x over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See them free>>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Bank of America, UnitedHealth, Intel, UPS and Celgene
For Immediate Release
Chicago, IL – August 01, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog includeBank of America (NYSE:BAC – Free Report), UnitedHealth (NYSE:(UNH - Free Report) – Free Report), Intel (NASDAQ:INTC – Free Report), UPS (NYSE:(UPS - Free Report) – Free Report) and Celgene (NASDAQ: – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for B of A, UnitedHealth, Intel & More
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Bank of America (NYSE:(BAC - Free Report) – Free Report), UnitedHealth (NYSE:(UNH - Free Report) – Free Report), Intel (NASDAQ:(INTC - Free Report) – Free Report) and Celgene (NASDAQ: – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Bank of America shares have outperformed the Zacks Major Regional Banks industry over the last six months, gaining +5.9% vs. +5.3%. The company’s second quarter 2017 earnings outpaced expectations. Improvement in net interest income, higher investment banking fees and lower provisions supported the results.
Rising interest rates, increase in loan and deposit balances, efforts to streamline and simplify operations, and potentially fewer regulations are expected to continue supporting the company's profitability going forward. However, fee income growth remains a key concern. Specifically, a fall in mortgage banking income owing to lower volumes and decline in refinancing along with uncertainty related to performance of capital markets are major concerns for the Zacks analyst.
(You can read the full research report on Bank of America here >>>).
Shares ofCelgene have gained +17.5% year to date, outperforming the Zacks Biomedical and Genetics sector which has gained +10.5% over the same period. The company’s second-quarter results were strong with the company beating on both earnings and sales estimates. Revlimid continued to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration.
The Zacks analyst likes the consecutive increase in annual earnings guidance. Celgene continues to progress with its label expansion efforts and pipeline development with sNDA submission for Revlimid in newly diagnosed multiple myeloma targeted for first-quarter 2018. However, Celgene is highly dependent on Revlimid while foreign exchange headwinds are expected to continue.
(You can read the full research report on Celgene here >>>).
UnitedHealth’s robust Government business and continued strong growth at Optum are driving long-term growth. Its international business, growing membership and strong capital position are the other positives. In the most recently reported quarter, the company reported better-than-expected earnings, driven by an increase in revenues and membership.
Encouraged by its impressive first-half earnings, the company raised 2017 guidance. Meanwhile, the company has reduced its exposure to the troubled public exchange business. Though this move will shield it from losses in this business, premium revenues are likely to be affected. UnitedHealth shares have underperformed the Zacks Medical Insurance industry in the year-to-date period (up +19.7% vs. +22.2%).
(You can read the full research report on UnitedHealth here >>>).
Shares of Intel have gained only +2.5% since election results were announced on Nov 8, in contrast to the broader Technology sector (up +18.6%) as well as the red-hot semiconductors space (up +28.3%). Intel’s second-quarter 2017 results demonstrated the company’s growing focus on the data-centric part of its business.
The recent launch of Xeon Scalable is anticipated to benefit its footprint in the data center as well as AI and IoT space, going forward. Further, anticipated improvement in cost structure and lower spending, primarily due to improving operational efficiency will aid in expansion of margins over time. Additionally, aggressive share buybacks will boost the bottom line in 2017.
Intel’s weak price performance can be attributed to growing competition from AMD in the data center space. Meanwhile, top-PC makers like HP, Lenovo, and Asus are set to launch PCs based on Qualcomm’s ARM-based Snapdragon processor, which intensifies competition for Intel. This is a significant headwind amid declining PC shipments.
(You can read the full research report on Intel here >>>).
Other noteworthy reports we are featuring today include UPS (NYSE:(UPS - Free Report) – Free Report).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 to Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and 90.2% respectively.
This outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11x over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See them free>>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Get the full Report on BAC - FREE
Get the full Report on UNH - FREE
Get the full Report on INTC – FREE
Get the full Report on CELG - FREE
Get the full Report on UPS - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.